• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    National Vision Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    4/29/25 6:05:32 AM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email
    false 0001710155 0001710155 2025-04-28 2025-04-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K 

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date Earliest Event reported): April 28, 2025

     

    National Vision Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-38257 46-4841717
    (State or other jurisdiction of
    incorporation)
    (Commission File Number) (IRS Employer Identification No.)

     

    2435 Commerce Avenue

    Bldg. 2200

    Duluth, Georgia 30096-4980

    (Address of principal executive offices, including zip code)

     

    (770) 822-3600

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8−K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Title of each class Trading
    Symbol(s)
    Name of each exchange on which
    registered
    Common stock, par value $0.01 per share EYE Nasdaq

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨ 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On April 28, 2025, the Board of Directors (the “Board”) of National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) approved the Company’s CEO succession plan (the “Succession Plan”). Under this plan, effective August 1, 2025, Alex Wilkes will succeed Reade Fahs as the Company’s Chief Executive Officer and will be appointed to the Company’s Board. Mr. Fahs will assume the role of Executive Chairman. D. Randolph Peeler, the current Chair of the Board, will assume the role of Lead Independent Director.

     

    Mr. Wilkes, 46, was appointed as president of National Vision in August of 2024. Previously, he served as President of the Americas at CooperVision, a global leader in contact lenses, since June 2022. Prior to CooperVision, Mr. Wilkes spent over a decade at EssilorLuxottica, a leading global eyewear company, in various roles including as Senior Vice President and General Manager of Pearle Vision from February 2016 to June 2022, where he was responsible for oversight of the brand.

     

    In connection with Mr. Wilkes’ appointment to Chief Executive Officer, the Company’s compensation committee approved certain changes to Mr. Wilkes’ compensation. In accordance with his new position and responsibilities, Mr. Wilkes’ salary was increased from $600,000 to $900,000, effective August 1, 2025, and his target annual cash bonus opportunity for 2025 was increased from $450,000 to $900,000. In addition, on August 1, 2025, Mr. Wilkes will receive a one-time, promotional grant of restricted stock units (“RSUs”) having a grant date value of $1,000,000, which will vest in three annual installments, conditioned upon his continued employment.

     

    Under the Succession Plan, Mr. Fahs entered an Executive Chair Agreement with the Company. Mr. Fahs’ salary will be reduced to $700,000 effective August 1, 2025. His target annual cash incentive opportunity remains unchanged for 2025 but will be reduced to $560,000 for 2026, and he will not receive an annual cash incentive award for 2027. In 2026, Mr. Fahs will receive an award of RSUs having a grant date value equal to $2,000,000 that vest in three annual installments, conditioned upon his continued employment through the date of the Company’s 2027 annual meeting of stockholders, which is when the term of the Executive Chair Agreement ends. If the Company terminates the Executive Chair Agreement without “cause” or Mr. Fahs resigns for “good reason” (as such terms are defined in the Executive Chair Agreement) before the end of the term, then, conditioned upon his execution and non-revocation of a general release of claims, Mr. Fahs will receive severance equal to the remaining salary that he would have earned through the end of the term, payable in installments in accordance with our normal payroll practices, plus his target cash bonus for the year of termination (if any), and continued vesting of his then-outstanding equity awards. A copy of the Executive Chair Agreement will be filed with the Company’s next quarterly report on Form 10-Q.

     

    There are no arrangements or understandings between Mr. Wilkes and any other person pursuant to which Mr. Wilkes was appointed to serve as Chief Executive Officer and a director of the Company. There are no family relationships between Mr. Wilkes and any of the Company’s directors or executive officers. Mr. Wilkes has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

     

    Additionally, Thomas V. Taylor, Jr., who joined the Board in 2018, will not stand for reelection at the 2025 annual meeting of stockholders (the “Annual Meeting”) and will be departing as a director immediately following the Annual Meeting. Mr. Taylor is currently the chair of the compensation committee. Mr. Taylor’s departure is in no way due to any disagreement with the Company, nor is it the result of a removal “for cause.” In connection with Mr. Taylor’s departure from the Board, the size of the Board will be reduced from eleven directors to ten at the time of the opening of the polls at the Annual Meeting. The size of the Board will be increased effective upon Mr. Wilkes joining the Board on August 1, 2025.

     

    Item 7.01Regulation FD Disclosure.

     

    On April 29, 2025, National Vision issued a press release announcing the Succession Plan. A copy of the press release is furnished with this report as Exhibit 99.1.

     

    The information in this Current Report on Form 8-K under Item 7.01 and Exhibit 99.1 attached hereto is being furnished to the SEC and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of National Vision’s filings with the SEC under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

     

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No. Description

     

    99.1 National Vision Holdings, Inc. Press Release dated April 29, 2025.
       
    104 Cover page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.

     

    This current report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934. These statements include statements related to our current beliefs and expectations regarding the performance of our industry, the Company’s strategic direction, market position, prospects and future results. You can identify these forward-looking statements by the use of words such as “outlook,” “guidance,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “projects,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Caution should be taken not to place undue reliance on any forward-looking statement as such statements speak only as of the date when made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Forward-looking statements are not guarantees and are subject to various risks and uncertainties, which may cause actual results to differ materially from those implied in forward-looking statements. Information about factors that could cause National Vision’s results to differ materially from those described in the forward-looking statements can be found in filings by National Vision with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 28, 2024, under the caption “Risk Factors,” and subsequently filed reports, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC.

     

     

     

     

    Signatures

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

     

        National Vision Holdings, Inc.
         
    Date: April 29, 2025 By: /s/ Jared Brandman
      Name: Jared Brandman
      Title: Senior Vice President, General Counsel and Secretary

     

     

     

    Get the next $EYE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    5/2/2023Overweight → Equal Weight
    Barclays
    3/31/2023$23.00Hold → Buy
    Loop Capital
    1/17/2023Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • National Vision Announces Participation in William Blair Growth Stock Conference

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that the Company is scheduled to present at the 45th annual William Blair Growth Stock Conference on Wednesday, June 4, 2025, at 9:20 a.m. Central Time. A live webcast of the presentation can be accessed in the "Investors" section of the Company's website at www.nationalvision.com/investors. The webcast will be archived and available on the website shortly after the event. About National Vision Holdings, Inc. National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of hel

      5/21/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Announces Settlement of 2025 Convertible Senior Notes

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the settlement of the remaining $84.8 million aggregate principal amount of 2.5% unsecured convertible senior notes due May 15, 2025 (the "2025 Convertible Notes"). The settlement was made with $59.8 million from cash on hand and the remaining borrowed under the Company's revolving credit facility. Chris Laden, Chief Financial Officer of National Vision, said, "Our strong cash generation and solid balance sheet support our ongoing approach to a balanced capital allocation strategy, which has included the opportunistic repurchases and the final settlement of our convertible notes. As we look ahe

      5/15/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    SEC Filings

    See more
    • SEC Form 10-Q filed by National Vision Holdings Inc.

      10-Q - National Vision Holdings, Inc. (0001710155) (Filer)

      5/8/25 8:36:28 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - National Vision Holdings, Inc. (0001710155) (Filer)

      5/7/25 6:05:18 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SEC Form DEF 14A filed by National Vision Holdings Inc.

      DEF 14A - National Vision Holdings, Inc. (0001710155) (Filer)

      4/29/25 6:22:58 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/14/24 12:33:08 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/12/24 4:45:48 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/4/24 1:18:26 PM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    See more

    $EYE
    Financials

    Live finance-specific insights

    See more

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • National Vision Appoints Alex Wilkes as CEO

      Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

      4/29/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

      Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

      3/17/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Christopher Laden as Chief Financial Officer

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of Christopher Laden as Chief Financial Officer, effective March 31, 2025. He will succeed Melissa Rasmussen who, as previously announced, will step down from the Company, effective March 3, 2025. "We are thrilled to welcome Chris to National Vision. He has a proven track record of successfully developing finance organizations into strong cross-functional business partners by focusing on accountability, employee development, and driving efficiencies through the use of digitization. His experience in both the service and optical industries will be instrumental as we move forward

      2/26/25 5:59:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Announces First Quarter 2025 Earnings Release and Conference Call

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings, Inc.

      4/24/25 8:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2024 Financial Results

      Strong Fourth Quarter Results Reflect Successful Execution on Store-Level Transformation Initiatives Introduced Targeted Initiatives to Broaden Appeal and Expand Customer Base Actions Taken to Reduce Costs and Strengthen Profitability Fourth quarter 2024 highlights: Net revenue from continuing operations of $437.3 million, an increase of 3.9% as compared to Q4 2023 Comparable store sales growth of 2.6% and Adjusted Comparable Store Sales Growth of 1.5% as compared to Q4 2023 Net loss from continuing operations of $(29.4) million, Diluted EPS from continuing operations of $(0.37) Adjusted Operating Income from continuing operations increased to $3.2 million from $(2.7) mill

      2/26/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Chief Executive Officer Fahs L Reade gifted 11,000 shares, decreasing direct ownership by 2% to 682,195 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/27/25 4:17:42 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SVP, CHIEF MERCH. & MC OFFICER Molony Megan sold $73,710 worth of shares (3,900 units at $18.90), exercised 12,206 shares at a strike of $15.07 and covered exercise/tax liability with 10,581 shares, decreasing direct ownership by 29% to 5,600 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/16/25 4:30:35 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SVP, Chief Technology Officer Acharya Ravi sold $225,060 worth of shares (12,000 units at $18.75), decreasing direct ownership by 51% to 11,700 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/25 4:37:10 PM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:27:52 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:26:51 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/24 8:01:46 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • National Vision upgraded by Citigroup with a new price target

      Citigroup upgraded National Vision from Neutral to Buy and set a new price target of $21.00

      5/9/25 8:39:42 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision upgraded by BofA Securities

      BofA Securities upgraded National Vision from Underperform to Buy

      5/7/25 2:46:43 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision downgraded by Goldman with a new price target

      Goldman downgraded National Vision from Buy to Neutral and set a new price target of $16.00 from $25.00 previously

      10/17/23 7:19:16 AM ET
      $EYE
      Ophthalmic Goods
      Health Care